Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from Taiwan
{{output}}
Background/purpose: Tenofovir alafenamide (TAF) has demonstrated non-inferior efficacy to tenofovir disoproxil fumarate (TDF) with improved bone and renal safety across diverse populations, including those with mild renal or hepa... ...